loperamide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   29 Trials   29 Trials   1503 News 


«12345678910111213...2223»
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Entyvio (vedolizumab) / Takeda
    Review, Journal, Checkpoint inhibition:  Checkpoint Inhibitor-Induced Colitis: An Update. (Pubmed Central) -  May 27, 2023   
    In more severe cases, corticosteroid treatment is mandatory. In refractory cases, off-label use of biological therapies (infliximab or vedolizumab) was proposed.
  • ||||||||||  amitriptyline / Generic mfg., loperamide / Generic mfg.
    Journal:  Decoration of ?-Cyclodextrin and Tuning Active Layer Chemistry Leading to Nanofiltration Membranes for Desalination and Wastewater Decontamination. (Pubmed Central) -  May 26, 2023   
    The membrane fabricated using TPC crosslinker (BCD-TA-TPC@PSf) showed higher % rejection for divalent ions (NaSO = 93%; MgSO = 92%; MgCl = 91%; CaCl = 84%) and micro-pollutants (Caffeine = 88%; Sulfamethoxazole = 90%; Amitriptyline HCl = 92%; Loperamide HCl = 94%) compared to the membrane fabricated using TMC crosslinker (BCD-TA-TMC@PSf). For the BCD-TA-TPC@PSf membrane, the flux was increased from 8 LMH (L/m.h) to 36 LMH as the transmembrane pressure was increased from 5 bar to 25 bar.
  • ||||||||||  capivasertib (AZD5363) / Otsuka, AstraZeneca
    Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2 (On Demand | Hall A; Poster Bd # 288) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_3259;    
    P3
    Clinical trial information: NCT04305496. >aGroup terms (preferred terms): diarrhea (diarrhea, frequent bowel movements, gastrointestinal hypermotility); rash (rash, rash macular, maculopapular rash, rash papular, rash pruritic) and hyperglycemia (blood glucose increased, hyperglycemia).
  • ||||||||||  Emestop (ramosetron hydrochloride) / Samyang Group
    Enrollment open:  5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS) (clinicaltrials.gov) -  Apr 25, 2023   
    P=N/A,  N=212, Recruiting, 
    >aGroup terms (preferred terms): diarrhea (diarrhea, frequent bowel movements, gastrointestinal hypermotility); rash (rash, rash macular, maculopapular rash, rash papular, rash pruritic) and hyperglycemia (blood glucose increased, hyperglycemia). Not yet recruiting --> Recruiting
  • ||||||||||  loperamide / Generic mfg.
    Preclinical, Journal:  Arctiin alleviates functional constipation by enhancing intestinal motility in mice. (Pubmed Central) -  Apr 24, 2023   
    A model of FC induced by loperamide (5 mg/kg) was established in male Institute of Cancer Research (ICR) mice...Arc decreased inflammation induction and aquaporin expression levels. Owing to its pro-intestinal motility property, Arc was shown to have a protective effect against FC and may thus serve as a promising therapeutic strategy for the management of FC.
  • ||||||||||  Recentin (cediranib) / AstraZeneca
    Trial completion date, Trial primary completion date, Monotherapy, Metastases:  Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) -  Apr 24, 2023   
    P2,  N=34, Active, not recruiting, 
    Owing to its pro-intestinal motility property, Arc was shown to have a protective effect against FC and may thus serve as a promising therapeutic strategy for the management of FC. Trial completion date: Apr 2023 --> Mar 2024 | Trial primary completion date: Apr 2023 --> Mar 2024
  • ||||||||||  Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
    PENICILLIN ALLERGY LABEL INCREASES HEALTH CARE UTILIZATION, MEDICATION USE AND C DIFFICILE INFECTION IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (South Hall A, Poster Hall - McCormick Place) -  Mar 23, 2023 - Abstract #DDW2023DDW_6641;    
    Trial completion date: Apr 2023 --> Mar 2024 | Trial primary completion date: Apr 2023 --> Mar 2024 PCN-A labeled patients were more likely to have received Metronidazole, Sulfamethoxazole, Quinolones, Clindamycin, Tetracyclines, and Macrolides (p<0.0001, Figure 1, Table 1)...Use of IBS-D medications was also increased in PCN-A patients including Loperamide (OR 1.46, p< 0.0001), Diphenoxylate (OR 1.41, p< 0.0001), Lactobacillus acidophilus (OR 1.92, p< 0.0001) and Rifaximin treatment courses (OR 1.17, p=0.045; average 4.4 vs 2.6, p< 0.0001)...Given recent interest in the microbiome
  • ||||||||||  Estring (estradiol) / Pfizer, Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Creon (pancrelipase delayed-release) / AbbVie, Eisai
    A CASE OF TRANSIENT EXOCRINE PANCREATIC DYSFUNCTION AFTER PFIZER-BIONTECH COVID-19 MRNA VACCINATION. (South Hall A, Poster Hall - McCormick Place) -  Mar 23, 2023 - Abstract #DDW2023DDW_5142;    
    PCN-A labeled patients were more likely to have received Metronidazole, Sulfamethoxazole, Quinolones, Clindamycin, Tetracyclines, and Macrolides (p<0.0001, Figure 1, Table 1)...Use of IBS-D medications was also increased in PCN-A patients including Loperamide (OR 1.46, p< 0.0001), Diphenoxylate (OR 1.41, p< 0.0001), Lactobacillus acidophilus (OR 1.92, p< 0.0001) and Rifaximin treatment courses (OR 1.17, p=0.045; average 4.4 vs 2.6, p< 0.0001)...Given recent interest in the microbiome We present a case of transient exocrine pancreatic insufficiency (EPI) that occurred after administration of the Pfizer-BioNTechCOVID-19 mRNA vaccine (Comirnaty
  • ||||||||||  loperamide / Generic mfg.
    Trial completion, Enrollment change, Surgery:  Effect of Treatment of Low Anterior Resection Syndrome After Rectal Cancer Surgery (clinicaltrials.gov) -  Mar 9, 2023   
    P=N/A,  N=45, Completed, 
    Materials and Kunming mice (half male and female), were randomly divided into six groups: normal group, 5-FU group (5-FU, 60 Active, not recruiting --> Completed | N=100 --> 45
  • ||||||||||  Biomarker, Journal:  Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. (Pubmed Central) -  Mar 7, 2023   
    We also used our biomarker gene expression signature to identify drugs that could be repurposed for treating anxiety, such as estradiol, pirenperone, loperamide, and disopyramide. Given the detrimental impact of untreated anxiety, the current lack of objective measures to guide treatment, and the addiction potential of existing benzodiazepines-based anxiety medications, there is a urgent need for more precise and personalized approaches like the one we developed.
  • ||||||||||  loperamide / Generic mfg.
    Constipation enhances gut-skin axis imbalance in a mouse model of acne vulgaris () -  Mar 4, 2023 - Abstract #ISID2023ISID_1258;    
    First, the constipation was induced by oral gavage of loperamide in six- to seven-week-old female C57BL/6 mice...Additionally, Rorc-/- mice showed resistance to the aggravation of acne due to constipation, suggesting the essential role of IL-17 cytokine in the gut-skin axis. Taken together, our mouse model supports the common knowledge that constipation aggravates acne vulgaris and is useful in enabling further investigation of the gut-skin axis.
  • ||||||||||  loperamide / Generic mfg.
    Review, Journal:  Diarrhea and Coronavirus Disease 2019 Infection. (Pubmed Central) -  Feb 27, 2023   
    Treatment for the diarrhea is intravenous fluid infusion and electrolyte supplementation as necessary, and symptomatic antidiarrheal therapy, including Loperamide, kaolin-pectin, or possible alternatives...Diarrhea is prominent in post-COVID-19 (long COVID-19), and is occasionally noted after COVID-19 vaccination. The spectrum of diarrhea in COVID-19 patients is presently reviewed including the pathophysiology, clinical presentation, evaluation, and treatment.
  • ||||||||||  methoxyamine (TRC102) / Tracon Pharma
    Trial completion date, Trial primary completion date, Combination therapy:  TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov) -  Feb 15, 2023   
    P1/2,  N=140, Recruiting, 
    Herein, we investigated the effects of Lacticaseibacillus paracasei JY062, Lactobacillus gasseri JM1, and the probiotic combination at 5 Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Feb 2024
  • ||||||||||  Trodelvy (sacituzumab govitecan-hziy) / Gilead
    Enrollment open, Metastases:  Preventive stRategy for IMMU132-relatED AEs in TNBC - PRIMED (clinicaltrials.gov) -  Feb 9, 2023   
    P2,  N=50, Recruiting, 
    In summary, it was demonstrated that HLP reduced loperamide-induced constipation in mice. Not yet recruiting --> Recruiting
  • ||||||||||  loperamide / Generic mfg.
    Preclinical, Journal:  Luteolin ameliorates loperamide-induced functional constipation in mice. (Pubmed Central) -  Feb 2, 2023   
    Additionally, luteolin decreased the upregulation of aquaporin (AQP)-3, AQP-4, and AQP-8 in the colon of FC mice. In summary, our data showed that luteolin might be an attractive option for developing FC-relieving medications.
  • ||||||||||  loperamide / Generic mfg.
    Journal:  Quantitative proteomic analysis reveals the effects of mu opioid agonists on HT22 cells. (Pubmed Central) -  Jan 27, 2023   
    We investigated the effects of loperamide, an agonist of the mu opioid receptor, on protein expression in HT22 cells using stable isotope labeling of amino acids in cell culture (SILAC), immobilized metal affinity chromatography (IMAC) enrichment, and high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS)...Results and Bioinformatic analysis revealed that mu opioid receptor agonism can induce distinct changes in the proteome of HT22 cells. These findings improve our understanding of narcotic drugs.
  • ||||||||||  loperamide / Generic mfg.
    Trial completion date, Trial primary completion date:  RCTFMTobesity: Randomized Controlled Trial of Fecal Microbiota Transplantation in Severe Obesity (clinicaltrials.gov) -  Jan 20, 2023   
    P=N/A,  N=60, Enrolling by invitation, 
    Two-week neratinib DE with loperamide as needed was particularly effective. Trial completion date: Dec 2022 --> May 2023 | Trial primary completion date: Jan 2022 --> May 2023